Evaluation Of Busulfan's Dose-Intensity In Patients Undergoing Allogeneic Stem Cell Transplantation (ASCT) With Two Different Fludarabine/Busulfan/ATG (FBA)-Based Reduced Intensity Conditioning (RIC) Regimens  by Hamadani, M. et al.
S280 Poster Session II328
PRELIMINARY RESULTS OF PHASE II TRIAL OF CLOFARABINEWITH PAR-
ENTERAL BUSULFAN (CLO/BU) FOLLOWED BY ALLOGENEIC RELATED
OR UNRELATED DONOR TRANSPLANTATION FOR THE TREATMENT OF
HEMATOLOGIC MALIGNANCIES
Agura, E.1,2, Berryman, R.B1,2, Luis, P.1,2, Estil, V.1,2, Tadic-
Ovcina,M.1,Woelfel, R.1, Fay, J.1,2 1Charles A Sammons Cancer Center,
Baylor University Medical Center, Dallas, TX; 2Texas Oncology P.A.,
Dallas, TX
Background: RIT regimens are now common, but relapse remains
a problem. To address this issue, we proposed and tested a ‘‘mid-in-
tensity’’ conditioning regimen using clofarabine (CLO) with busul-
fan (BU). We hypothesized that this combination would be well
tolerated and offer greater anti-leukemic efficacy than existing RIT
regimens.
Methods:We enrolled 20 patients on this IST, with AML(10), ALL
(1), CLL (1), MDS (2) and MDS-AML (6). 15 patients had prior
therapies. The conditioning was: CLO 40 mg/m2 iv daily x5, BU
3.2 mg/kg iv daily x2, followed by 1 rest day, followed by HSCT.
Donors were matched at A, B, C, DR and DQ using DNA SBT or
mid-res DNA typing. Mismatch# 1 antigen was allowed. GVHD
prophylaxis was Tacrolimus and MTX 5 mg/m2 iv.
Results: Endpoints included toxicity, incidence/severity of
AGVHD, and disease response.
Grade 4 hem toxicity occured in all patients. GCSF was used in
18 of 20 subjects. The median time to recovery of ANC was 15
days (d9 – d17). Donor engraftment (.80% donor chimerism at
d30) occurred in all patients by FISH and/or STR. 2 patients
had hand/foot syndrome (1 Gr. 3, related); 1 respiratory failure
(Gr. 3 possibly related) resolved completely; 1 patient had elevated
ALT/AST (Gr.4, related) which resolved once regimen completed;
other toxicities were #Gr. 2. There were no transplant related
mortalities.
AGVHD occurred in 15 patients within the first 100 days. Of
these, 80% were grade 1-2 and 20% grade 3-4. There were no deaths
attributed to AGVHD following the study regimen.
The disease responses are: 10 (56%) patients, refractory(4), in re-
lapse (1), active disease (5) prior to initiation of CLO/BU, achieved
CR by d30. 7 (39%) patients who were in CR at study entry, remain
so at d30. 2 patients were N/E for disease response at d30. One pa-
tient (w/CLL) acheived CR at d132. 4 (22%) patients relapsed. 9
(45%) patients expired from: cardiac arrest (1, d316); aspergillus
pneumonia (1, d158); TTP (1, d438); AGVHD – post DLI (1,
d175); relapse (4, d222 median); MSOF (1, d91). Of 18 evauable pa-
tients, 10 (55%) remain in remission with a median follow up of 401
days.
Conclusions: CLO/BU is a mid-intensity allo HSCT regimen
with promising antileukemic efficacy that seems to be well toler-
ated without significant cardiac, renal or pulmonary toxicities.
Furthermore, CLO/BU resulted in full donor engraftment by
day 30 in all patients. Enrolment is closed; collection of data is
ongoing.329
EVALUATION OF BUSULFAN’S DOSE-INTENSITY IN PATIENTS UNDERGO-
ING ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT) WITH TWO
DIFFERENT FLUDARABINE/BUSULFAN/ATG (FBA)-BASED REDUCED IN-
TENSITY CONDITIONING (RIC) REGIMENS
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We evaluated the effects of busulfan’s dose-intensity in patients
undergoing RIC ASCT at two different transplant centers. Forty-
three patients were conditioned with busulfan (0.8 mg/kg/dose IV
 8 doses), fludarabine (30 mg/m2/day, days -7 to -3), and 6 mg/
kg of ATG (L-FBA), while 23 patients received a ‘more-intense’
RIC with busulfan (130 mg/m2/day IV, days -6 to -3), fludarabine
(40 mg/m2/day, days -6 to -3), and 6 mg/kg of ATG (H-FBA).
Median age was 55 years. 84% (N5 56) had high-risk disease. 19patients (29%) received mismatched allografts. 55 patients (83%)
received grafts from unrelated donors. Baseline characteristics
were well balanced between the two cohorts, except for higher pro-
portion of unrelated donors in L-FBA group (p-value5 0.02). All
patients engrafted neutrophils and platelets (median 17 and 13
days, respectively). There were no graft rejections. Compared to
patients receiving H-FBA, those receiving L-FBA had fewer
CMV reactivations (48% vs. 30%; p-value5 0.15), bacterial infec-
tions (69% vs. 43%; p-value5 0.004) and slightly lower rates of
1-year non-relapse mortality (17% vs. 7%; p-value5 0.19). Com-
pared to L-FBA, H-FBA did not reduce relapse rates (34% vs.
43%; p-value5 0.49). Rate of grade II-IV acute GVHD (30% vs.
52%; p-value5 0.08) favored L-FBA, while incidence rate of
chronic GVHD (40% vs. 40%; p-value5 0.11) were similar. Me-
dian day +90 and +360 chimerism for both groups was 100%. 38
patients (58%) were in CR after ASCT. The median follow-up
of surviving patients is 12 months. Compared to patients receiving
H-FBA, ones receiving L-FBA showed a significantly superior
1-year overall survival (44% vs. 68% p-value5 0.02) and trend
toward improved 1-year progression free survival (33% vs. 60%
p-value5 0.07). Our preliminary, retrospective data suggests that
L-FBA maintains acceptable rates of disease relapse, non-relapse
mortality, full-donor cell chimerism and GVHD control compared
to H-FBA, and may be associated with lower rates of infectious
complications and improved survival.330
INFLUENCE OF COMORBIDITIES ON TRANSPLANT OUTCOMES IN PA-
TIENTS AGED 50 YEARS OR MORE AFTER MYELOABLATIVE CONDITION-
ING INCORPORATING FLUDARABINE, BUSULFAN AND ATG
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Non-myeloablative (NST) and reduced intensity (RIC) regimens
are offered to older patients (pts) and/or those with comorbidities
because the morbidity and mortality attributable to fully myeloabla-
tive conditioning is thought to be unacceptably high. All such pa-
tients receive myeloablative protocols in our program, outcomes
have been analyzed in order to determine whether this practice is jus-
tifiable. Between 1999 and 2008 207 patients (pts) with hematologic
malignancy aged 50–66 years (median 56) received blood cell (87%)
or marrow transplants after conditioning with Flu 50 mg/m2 daily
5 and IV Bu 3.2 mg/kg daily 4. 90 (43%) had additional total body
irradiation (TBI) 200 cGy  2. Graft-versus-host disease (GVHD)
prophylaxis was cyclosporin A, methotrexate and Thymoglobulin
(Genzyme) 4.5 mg/kg total dose. Donors were matched siblings in
125 (60%) mismatched related in 11 (5%), 10/10 matched unrelated
in 54 (26%) and mismatched unrelated in 17(8%). 74 pts (36%) had
low-risk (LR, acute leukemia CR1/CR2, CML CP1) disease. As de-
fined by the HCT-CI scoring system 117 (57%) pts scored 0 (low
HCT-CI), 68 (33%) 1 or 2 (intermediate HCT-CI) and 22 (11%,)
$3 (high HCT-CI). Transplant risk factors were similar between in-
termediate and high HCT-CI groups. As NRM (33% and 33% vs
24% and 48%, p5 ns) and DFS (46% and 37% vs 64% and 43%,
p5 ns) at 1 and 5 years respectively were also similar, outcomes in
these 2 groups were combined for more robust analysis. The propor-
tion of pts with LR disease was higher in those with comorbidities
(intermediate and high HCT-CI) (49% vs 26%, p5 0.0006) than
those without. OS was 56% and 39% vs 74% and 54%
(p5 0.008), DFS 50% and 38% vs 68% and 49% (p5 0.03),
NRM 31% and 39% vs 15% and 19% (p5 0.003) and relapse
26% and 36% vs19% and 39% (p5 ns) respectively at 1 and 5 years.
In 48 AML pts in CR1 & CR2, 27 (56%) with comorbidities, receiv-
ing this protocol with TBI DFS at 5 years was 66%. We conclude
that: 1. Comorbidities influence NRM with this regimen although
cannot confirm that the high HCT-CI group is at higher risk than
the intermediate. 2. Age alone should not be an indication to prefer
a less intense protocol particularly in a condition such as AML where
there is an effect of regimen intensity on relapse. 3. Although NRM
